One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Crohn's Disease Diagnostics and Therapeutics Market

[ 英語タイトル ] Crohn's Disease Diagnostics and Therapeutics Market (2020 - 2025)

Product Code : MDHC0088794
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 113
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbvie Inc.
- Celgene Corporation
- Genetech
- Johnson & Johnson
- Pfizer Inc.
- Prometheus Laboratories Inc. (Nestle)
- Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
- Takeda's Pharmaceutical Ltd

[Report Description]

The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.

- Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
- The increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies for the development of novel treatment options, is expected to provide the studied market with high growth potential.

Key Market Trends

Anti-inflammatory Agents Led the Market in 2018

Anti-inflammatory agents had been continuing to lead as the largest sub-segment under the therapeutics segment of the market studied, in 2018, due to their higher efficacy, compared to immunosuppressant and analgesic. Immune system suppressors are expected to be the fastest-growing segment, owing to the reduction in surgeries and hospitalization rates.

A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for the treatment of Crohn's disease.

North America Holds the Largest Market Share

North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market, due to the increasing prevalence of Crohn's disease in the region. Additionally, the Asia-Pacific region is expected to register high growth during the forecast period.

According to the Center for Disease Control and Prevention (CDC), it has been estimated that about 1.3 million people suffer from inflammatory bowel disorder (IBD), in the United States. IBD prevalence includes the incidence of ulcerative colitis (UC) and Crohn's disease. In this region, urbanization is a potential contributing factor to the increasing prevalence of Crohn's disease. The incidence of CD has been attributed to the result of the “westernization” of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals.

Overall, Crohn’s disease has been affecting the North American and Western European countries more heavily than others, with more than 750,000 people living with Crohn's disease in the United States alone.

Competitive Landscape

The Crohn's disease diagnostics and therapeutics market has growth opportunities both in the developing and developed nations of the world. However, the US region has been controlling a majority of the market share, which can be attributed to the higher prices of pharmaceuticals and the greater prevalence of diagnosed cases of Crohn’s disease in the region. The higher share of the US market can also be attributed to the high annual cost of therapy (ACOT) of Stelara (Johnson & Johnson) and the ACOT of Risankizumab (AbbVie) in the US market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
4.2.2 Demand for Prompt Diagnosis
4.2.3 Affected Population Increasing with Time
4.3 Market Restraints
4.3.1 No Specific Treatment or Drug Available in the Market
4.3.2 Lack of Awareness among the People and Symptom Similarity with Other Gastrointestinal Diseases
4.3.3 Lack of Cost-effective Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Diagnostics
5.1.1 Blood Test
5.1.2 Fecal Test
5.1.3 Colonoscopy
5.1.4 Flexible Sigmoidoscopy
5.1.5 Computerised Tomography
5.1.6 Magnetic Resonance Imaging
5.1.7 Other Diagnostic Tests (Capsule Endoscopy, etc.)
5.2 Treatment
5.2.1 Medication Anti-inflammatory Agents Immunosuppressants Analgesics and Antipyretics Other Medications
5.2.2 Surgery
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Celgene Corporation
6.1.3 Genetech
6.1.4 Johnson & Johnson
6.1.5 Pfizer Inc.
6.1.6 Prometheus Laboratories Inc. (Nestle)
6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
6.1.8 Takeda's Pharmaceutical Ltd




Recommended reports